A novel class of antibodies that binds to a previously untargeted portion of the malaria parasite could lead to new prevention methods, according to a study from researchers at the National Institutes of Health (NIH) published in Science.  

Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the most common in African countries where the burden of malaria is largest. 

Anti-malarial monoclonal antibodies (mAbs) are a promising new tool that have been shown to be safe and efficacious against infection with P. falciparum in adults and children in early clinical trials.  

The anti-malarial mAbs evaluated in trials in malaria-endemic regions target the P. falciparum sporozoite – the life stage of the parasite that is transmitted from mosquitoes to people. By binding to and neutralising the sporozoite, the mAbs prevent sporozoites from infecting the liver, where they otherwise develop into blood-stage parasites that infect blood cells and cause disease and death. 

The most promising anti-malarial mAbs tested in humans to date bind to a protein on the sporozoite surface called the circumsporozoite protein (PfCSP) at locations near to or containing amino acid repeats in a region called the central repeat region. 

A protective immune response

Led by scientists at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the research team isolated human mAbs produced in response to whole sporozoites, rather than to specific parts of the parasite. One mAb, named MAD21-101, was found to be the most potent, providing protection against P. falciparum infection in mice. 

The new mAb binds to an epitope on PfCSP outside of the central repeat region that is conserved between different strains of P. falciparum. Notably, the epitope, called pGlu-CSP, is exposed only after a specific step in the development of the sporozoite, but it is widely accessible on the sporozoite surface – a scenario that the researchers say could mean pGlu-CSP would be effective at eliciting a protective immune response if used in a vaccine.  

As pGlu-CSP is not included in currently used malaria vaccines, mAbs targeting this epitope are unlikely to interfere with the efficacy of these vaccines if the vaccines and mAbs are co-administered. Therefore, this new class of antibodies may be suitable to prevent malaria in at-risk infants who have not yet received a malaria vaccine, but may receive one in the future.

Diana Spencer, Senior Digital Content Editor, DDW